Back to Search Start Over

microRNA-130b-3p Contained in MSC-Derived EVs Promotes Lung Cancer Progression by Regulating the FOXO3/NFE2L2/TXNRD1 Axis

Authors :
Quanwei Guo
Jun Yan
Tieniu Song
Chenghua Zhong
Jun Kuang
Yijun Mo
Jianfeng Tan
Dongfang Li
Zesen Sui
Kaican Cai
Jianhua Zhang
Source :
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 132-146 (2021)
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

This study aimed to explore the molecular mechanism by which mesenchymal stem cells (MSCs) mediate lung cancer progression. Extracellular vesicles (EVs) were isolated from transfected or untransfected MSCs, and were co-cultured with lung cancer cells with/without microRNA-130b-3p (miR-130b-3p) inhibitor, mimic, overexpression plasmids of FOXO3/NFE2L2, or shRNAs. CCK-8 assay, colony formation, transwell assay, and flow cytometry were carried out to determine the biological functioning of lung cancer cells. Furthermore, FOXO3, Keap1, NFE2L2, and TXNRD1 expression was determined by qRT-PCR and western blot analysis. A tumor xenograft mouse model was used to determine role of EVs-miR-130b-3p and its target FOXO3 in lung cancer progression in vivo. miR-130b-3p was highly expressed in lung cancer tissues and MSC-derived EVs. Moreover, the MSC-derived EVs transferred miR-130b-3p to lung cancer cells to promote cell proliferation, migration, and invasion while repress cell apoptosis. miR-130b-3p directly targeted FOXO3, and FOXO3 elevated Keap1 expression to downregulate NFE2L2, thus inhibiting TXNRD1. FOXO3 overexpression or silencing of NFE2L2 or TXNRD1 diminished lung cancer cell proliferation, invasion, and migration but enhanced apoptosis. EV-delivered miR-130b-3p or FOXO3 silencing promoted lung cancer progression in vivo. In summary, MSC-derived EVs with upregulated miR-130b-3p suppressed FOXO3 to block the NFE2L2/TXNRD1 pathway, thus playing an oncogenic role in lung cancer progression.

Details

Language :
English
ISSN :
23727705
Volume :
20
Issue :
132-146
Database :
Directory of Open Access Journals
Journal :
Molecular Therapy: Oncolytics
Publication Type :
Academic Journal
Accession number :
edsdoj.59159614016b4d95af0d273a8301bb33
Document Type :
article
Full Text :
https://doi.org/10.1016/j.omto.2020.09.005